Therapix Biosciences Ltd. resolved to terminate the employment of all of the Company’s employees, except for the Company’s Interim Chief Executive Officer, Dr. Ascher Shmulewitz, who will remain in his position. In accordance with the terms of their respective employment agreements, the Company’s Chief Financial Officer, Mr. Oz Adler, and Chief Technologies Officer, Dr. Adi Zuloff-Shani, are each entitled to a 90 day notice period and will remain in their positions until March 30, 2020. In addition, on December 31, 2019, Dr. Yafit Stark and Mr. Zohar Heiblum resigned from the Company’s Board of Directors. The decision to resign of each of Dr. Stark and Mr. Heiblum did not result from any disagreement with the Company.